Experts interviewed in this report include:
· Dr. Merit Ester Cudkowicz, Chief of Neurology at Massachusetts General Hospital
· Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured by an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
Insight Pharma Reports also engineered a table of clinical trial information and pipeline data from multiple databases related to ALS. This table features companies, targets, clinical phases, and brief target/product descriptions.
For more information and to purchase this Insight Pharma Report, visit: http://www.insightpharmareports.com/
or contact Kerri Kelley at firstname.lastname@example.org or 781-972-1347.
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/